Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off
Source: SeekingAlpha
2026-02-12 12:43:18 ET
Investment Overview
Organon ( OGN ), the New Jersey-headquartered global healthcare company, reported its Q4 and full-year 2025 earnings earlier today, and somewhat predictably, results appear to have disappointed the market. The stock is down >10% at the time of writing, priced at $6.8, and the market cap stands at ~$1.78bn....
Read the full article on Seeking Alpha
For further details see:
Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off
Organon & Co.
NASDAQ: OGN
OGN Trading
-0.62% G/L:
$6.44 Last:
894,009 Volume:
$6.45 Open:
OGN Latest News
February 27, 2026 08:00:00 am
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 23, 2026 07:30:00 am
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
OGN Stock Data
$2,031,766,457
254,887,247
0.05%
304
N/A
Pharmaceuticals
Healthcare
US
Jersey City
